# The National Security and Investment Act 2021 (Notifiable Acquisition) (Specification of Qualifying Entities) Regulations 2021, Paragraph 6: Exceptions – human or veterinary medicines or immunomodulatory approaches


(1) Exceptions to the activities described in paragraph 2 are the ownership, ownership of intellectual property or development of the matters set out in sub-paragraph (2) that employ synthetic biology at any stage of the development or production, unless the circumstances set out in sub-paragraph (3) apply.
(2) The matters referred to in sub-paragraph (1) are—
(a) human or veterinary medicines;
(b) immunomodulatory approaches.
(3) The circumstances referred to in sub-paragraph (1) are where the matter described in sub-paragraph (2)—
(a) has a synthetic biology technology that could be employed or modified to produce, deliver or produce and deliver—
(i) toxic chemicals to achieve an incapacitating or lethal effect on humans or animals;
(ii) materials restricted under Schedule 5 to the Anti-terrorism, Crime and Security Act 2001; or
(b) uses substances or pathogens set out in Schedule 5 to the Anti-terrorism, Crime and Security Act 2001.

---
Source: https://www.legislation.gov.uk/ukdsi/2021/9780348226935/schedule/16/paragraph/6 (the official version)
Page: https://openlegislation.uk/draft-national-security-and-investment-act-2021-notifiable-acquisition-specification-of-qualifying-entities-regulations-2021/schedule-16/paragraph-6
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.

